iBio updates corporate presentation focused on antibodies for obesity and cardiometabolic diseases

iBio, Inc.

Corporate presentation dated September 2026 filed as Exhibit 99.1; highlights breakthrough antibodies for obesity and cardiometabolic diseases.
No specific pipeline milestones, financial figures, or clinical data disclosed in the filing excerpt.
Filing notes forward-looking statements and risks including regulatory approvals, financing, and Nasdaq listing maintenance.
Presentation updated for meetings with investors, analysts, and others; no other material events reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.